Nghiên cứu tiền lâm sàng về PAI2 gắn nhãn 213Bi trong việc kiểm soát ung thư tụy vi di căn

SF Sener A Fremgen HR Menck et al. (1999) ArticleTitlePancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database J Am Coll Surgeons 189 1–7 Occurrence Handle1:STN:280:DyaK1MzivVWlsg%3D%3D M Yamamoto O Ohashi Y Saitoh (1998) ArticleTitleJapan Pancreatic Cancer Registry: current status Pancreas 16 238–42 Occurrence Handle10.1097/00006676-199804000-00006 Occurrence Handle1:STN:280:DyaK1c3gvVCnsA%3D%3D Occurrence Handle9548661 KC Conlon DS Klimstra MF Brennan (1996) ArticleTitleLong-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors Ann Surg 223 273–279 Occurrence Handle1:STN:280:BymC1Mbgtlc%3D Occurrence Handle8604907 DM Goldenberg (2002) ArticleTitleTargeted therapy of cancer with radiolabeled antibodies J Nucl Med 43 693–713 Occurrence Handle1:CAS:528:DC%2BD38XktlOlur0%3D Occurrence Handle11994535 TM Behr B Wormann M Gramatzki et al. (1999) ArticleTitleLow- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies Clin Cancer Res 5 3304s–14s Occurrence Handle1:CAS:528:DyaK1MXnsVShtLc%3D Occurrence Handle10541379 DM Goldenberg (2001) ArticleTitleThe role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: the coming of age of radioimmunotherapy Crit Rev Oncol Hematol 39 195–201 Occurrence Handle1:STN:280:DC%2BD38%2Fit1ahsQ%3D%3D Occurrence Handle11418316 DV Gold DE Modrak K Schutsky et al. (2004) ArticleTitleCombined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft Int J Cancer 109 618–26 Occurrence Handle10.1002/ijc.20004 Occurrence Handle1:CAS:528:DC%2BD2cXislCis7s%3D Occurrence Handle14991585 MS Kaminski J Estes KR Zasadny et al. (2000) ArticleTitleRadioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 96 1259–66 Occurrence Handle1:CAS:528:DC%2BD3cXlvF2it7k%3D Occurrence Handle10942366 MR McDevitt G Sgouros RD Finn et al. (1998) ArticleTitleRadioimmunotherapy with alpha-emitting nuclides Eur J Nucl Med 25 1341–51 Occurrence Handle10.1007/s002590050306 Occurrence Handle1:CAS:528:DyaK1cXlsV2lu7s%3D Occurrence Handle9724387 BJ Allen (1999) ArticleTitleCan alpha-immunotherapy succeed where other systemic modalities have failed Nucl Med Commun 20 205–7 Occurrence Handle1:STN:280:DyaK1M7ptlShug%3D%3D Occurrence Handle10093068 SJ Kennel R Boll M Stabin et al. (1999) ArticleTitleRadioimmunotherapy of micrometastases in lung with vascular targeted 213Bi Br J Cancer 80 175–84 Occurrence Handle1:CAS:528:DyaK1MXjtFyksb8%3D Occurrence Handle10389994 B Allen N Blagojevic (1997) ArticleTitleAlpha and beta emitting radiolanthanides in targeted cancer therapy Nucl Med Commun 20 205–7 Y Li SM Rizvi M Ranson et al. (2002) ArticleTitle213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model Br J Cancer 86 1197–203 Occurrence Handle10.1038/sj.bjc.6600179 Occurrence Handle1:CAS:528:DC%2BD38XjvFGisbs%3D Occurrence Handle11953871 AM Ballangrud WH Yang S Palm et al. (2004) ArticleTitleAlpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression Clin Cancer Res 10 4489–97 Occurrence Handle1:CAS:528:DC%2BD2cXlsVWlurw%3D Occurrence Handle15240541 C Seidl H Schrock S Seidenschwang et al. (2005) ArticleTitleCell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death Eur J Nucl Med Mol Imag 32 274–85 Occurrence Handle1:CAS:528:DC%2BD2MXis1ajt7Y%3D GJ Beyer M Miederer S Vranjes-Duric et al. (2004) ArticleTitleTargeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab Eur J Nucl Med Mol Imag 31 547–54 Occurrence Handle1:CAS:528:DC%2BD2cXitFygsLo%3D JG Jurcic SM Larson G Sgouros et al. (2002) ArticleTitleTargeted alpha particle immunotherapy for myeloid leukemia Blood 100 1233–9 Occurrence Handle1:CAS:528:DC%2BD38Xmt12itL8%3D Occurrence Handle12149203 M Schmitt OG Wilhelm U Reuning et al. (2000) ArticleTitleThe urokinase plasminogen activation system as a novel target for tumour therapy Fibrinol Proteol 14 114–32 Occurrence Handle10.1054/fipr.2000.0079 Occurrence Handle1:CAS:528:DC%2BD3cXksVKht7s%3D J Pollanen RW Stephens A Vaheri (1991) ArticleTitleDirected plasminogen activation at the surface of normal and malignant cells Adv Cancer Res 57 273–328 Occurrence Handle1:CAS:528:DyaK38XhslWit7w%3D Occurrence Handle1950706 PA Andreasen R Egelund HH Petersen (2000) ArticleTitleThe plasminogen activation system in tumor growth, invasion, and metastasis Cell Mol Life Sci 57 25–40 Occurrence Handle1:CAS:528:DC%2BD3cXhslOrsrk%3D Occurrence Handle10949579 BM Mueller YB Yu WE Laug (1995) ArticleTitleOverexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice Proc Nat Acad Sci U.S.A. 92 205–9 Occurrence Handle1:CAS:528:DyaK2MXjtVegu7Y%3D K Marutsuka Y Hasui Y Asada et al. (1995) ArticleTitleEffects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6 Clin Exp Metastasis 13 116–22 Occurrence Handle10.1007/BF00133616 Occurrence Handle1:CAS:528:DyaK2MXlsFamt7Y%3D Occurrence Handle7882614 EK Kruithof MS Baker CL Bunn (1995) ArticleTitleBiological and clinical aspects of plasminogen activator inhibitor type 2 Blood 86 4007–24 Occurrence Handle1:CAS:528:DyaK2MXpslakurk%3D Occurrence Handle7492756 MS Baker P Bleakley GC Woodrow et al. (1990) ArticleTitleInhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation Canc Res 50 4676–84 Occurrence Handle1:CAS:528:DyaK3cXkvFGmsLs%3D F Al-Ejeh D Croucher M Ranson (2004) ArticleTitleKinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines Exp Cell Res 297 259–71 Occurrence Handle1:CAS:528:DC%2BD2cXkvVKmtr8%3D Occurrence Handle15194441 C Apostolidis R Carlos-Marquez W Janssens et al. (2001) ArticleTitleCancer treatment using Bi-213 and Ac-225 in radioimmunotherapy Nucl News 44 29–33 M Ranson Z Tian NM Andronicos et al. (2002) ArticleTitleIn vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells Breast Cancer Res Treat 71 149–59 Occurrence Handle10.1023/A:1013850107791 Occurrence Handle1:CAS:528:DC%2BD38XitFehsLo%3D Occurrence Handle11881911 Y Gavrieli Y Sherman SA Ben-Sasson (1992) ArticleTitleIdentification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation J Cell Biol 119 493–501 Occurrence Handle10.1083/jcb.119.3.493 Occurrence Handle1:CAS:528:DyaK38XmtVyhsbs%3D Occurrence Handle1400587 M Gleave JT Hsieh CA Gao et al. (1991) ArticleTitleAcceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts Cancer Res 51 3753–61 Occurrence Handle1:STN:280:By6B1M3kvVA%3D Occurrence Handle1712249 BJ Allen Z Tian SM Rizvi et al. (2003) ArticleTitlePreclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 Br J Cancer 88 944–50 Occurrence Handle10.1038/sj.bjc.6600838 Occurrence Handle1:CAS:528:DC%2BD3sXitFegtrk%3D Occurrence Handle12644835 W Wang JL Abbruzzese D Evans et al. (1999) ArticleTitleOverexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA Oncogene 18 4554–63 Occurrence Handle1:CAS:528:DyaK1MXlslCrtbc%3D Occurrence Handle10467400 D Cantero H Friess J Deflorin et al. (1997) ArticleTitleEnhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma Br J Cancer 75 388–95 Occurrence Handle1:STN:280:ByiC2s3ktVQ%3D Occurrence Handle9020484 Y Takeuchi A Nakao A Harada et al. (1993) ArticleTitleExpression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study Am J Gastroenterol 88 1928–33 Occurrence Handle1:CAS:528:DyaK2cXhvVynt74%3D Occurrence Handle8237943 RM Macklis JY Lin B Beresford et al. (1992) ArticleTitleCellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis Radiation Research 130 220–6 Occurrence Handle1:CAS:528:DyaK38XisFWiurs%3D Occurrence Handle1574578 F Al-Ejeh D Croucher M Ranson (2004) ArticleTitleKinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalsiation by carcinoma cell lines. Exp Cell Res 297 259–71 Occurrence Handle1:CAS:528:DC%2BD2cXkvVKmtr8%3D Occurrence Handle15194441 M Harms-Ringdahl P Nicotera IR Radford (1996) ArticleTitleRadiation induced apoptosis Mutat Res 366 171–9 Occurrence Handle1:CAS:528:DyaK28Xnt1Oit7k%3D Occurrence Handle9001584 JF Ward (1994) ArticleTitleThe complexity of DNA damage: relevance to biological consequences Int J Radiat Biol 66 427–32 Occurrence Handle1:CAS:528:DyaK2MXisFCkurw%3D Occurrence Handle7983426 Errol C Friedberg Graham C Walker W Siede (1995) DNA Repair and Mutagenesis ASM Press Washington D.C BJ Allen C Raja SMA Rizvi et al. (2004) ArticleTitleTargeted alpha therapy for cancer Phys Med Biol 49 3703–12 Occurrence Handle1:CAS:528:DC%2BD2cXnvVCqtL4%3D Occurrence Handle15446799